Business
Biotech IPOs and Pharma M&A
Top bankers tell CNBC that the biotech initial public offering (IPO) window is opening, but major pharmaceutical mergers and acquisitions continue to set the pace due to pressure on drug pipelines.
Coverage timeline — 1 article
CNBC
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
2026-06-16 05:00 UTC